- Member Benefits
- Manage your personalised Watchlist.
- Set up an online Virtual Portfolio.
- Participate in Share Chat.
- See more trades and director dealings.
- Play the Fantasy Share Trading Game.
Share:
HomeShare PricesStock PickerFinancial DiaryUK IndicesUK Industry SectorsCompany LookupShare RisersShare FallersBroker RatingsFinance GlossarySMS ServicesShare ChatFinance NewsBlogsLive PricesShares BookshopFinance ToolsMembers
Latest Share Chat
1spatial Holdings Share News (SPA)
Share News for 1spatial Holdings (SPA)
| Share Price: 6.875 | Bid: 6.50 | Ask: 7.00 | Change: 0.125 (+1.85%) |  | ||||||
| ||||||||||
SR Pharma annual losses widen
Fri, 30th Mar 2007 07:52
LONDON (AFX) - SR Pharma PLC, which specialises in RNAi-based therapeutics, reported widening
The company also said it plans to change its name to Silence Therapeutics.
Pretax losses in 2006 came in at 3.9 mln stg, compared to 3.6 mln the previous year.
Revenues surged four-fold to 1.95 mln stg, while R&D spend almost doubled to 3.2 mln stg.
During 2007 the group is forecasting a significant increase in R&D and infrastructure costs, as its lead molecules move into the clinic for human testing, and as US operations are set up.
SR Pharma said those costs will be funded through a continuation of collaboration and licensing deals with major pharmaceutical and biotechnology companies, on which it is in talks with a number of potential parties.
The company has called an Extraordinary General Meeting to approve the name change, and permission to issue new shares.
The group ended the year with 8.8 mln stg in cash.
SR Pharma shares, which have surged 440 pct in the last six months, closed Thursday at 81 pence, valuing the company at 92 mln stg.
amy.brown@thomson.com
ab
COPYRIGHT
Copyright AFX News Limited 2007. All rights reserved.
The copying, republication or redistribution of AFX News Content, including by framing or similar means, is expressly prohibited without the prior written consent of AFX News.
AFX News and AFX Financial News Logo are registered trademarks of AFX News Limited
LONDON (AFX) - SR Pharma PLC, which specialises in RNAi-based therapeutics, reported widening
annual losses on higher research and development costs, and forecast a significant hike in spending this year.
The company also said it plans to change its name to Silence Therapeutics.
Pretax losses in 2006 came in at 3.9 mln stg, compared to 3.6 mln the previous year.
Revenues surged four-fold to 1.95 mln stg, while R&D spend almost doubled to 3.2 mln stg.
During 2007 the group is forecasting a significant increase in R&D and infrastructure costs, as its lead molecules move into the clinic for human testing, and as US operations are set up.
SR Pharma said those costs will be funded through a continuation of collaboration and licensing deals with major pharmaceutical and biotechnology companies, on which it is in talks with a number of potential parties.
The company has called an Extraordinary General Meeting to approve the name change, and permission to issue new shares.
The group ended the year with 8.8 mln stg in cash.
SR Pharma shares, which have surged 440 pct in the last six months, closed Thursday at 81 pence, valuing the company at 92 mln stg.
amy.brown@thomson.com
ab
COPYRIGHT
Copyright AFX News Limited 2007. All rights reserved.
The copying, republication or redistribution of AFX News Content, including by framing or similar means, is expressly prohibited without the prior written consent of AFX News.
AFX News and AFX Financial News Logo are registered trademarks of AFX News Limited
SR Pharma plans more pre-clinical Atu027 tests, gets AtuRNAi milestone payment
LONDON (Thomson Financial) - SR Pharma PLC said it intends to carry out more pre-clinical testing on its lead molecule Atu027, its first RNAi ca[26 Apr '07]
SR Pharma chairman Iain Ross buys 100,000 shares in co at 75.75p each
LONDON (AFX) - SR Pharma PLC said chairman Iain Ross yesterday bought 100,000 shares at 75.75 pence each, giving him a 0.09 pct stake in the com[3 Apr '07]
SR Pharma annual losses widen
LONDON (AFX) - SR Pharma PLC, which specialises in RNAi-based therapeutics, reported widening annual losses on higher research and development c[30 Mar '07]
UK smallcap opening - Advent Air ticks up on interim profits surge
LONDON (AFX) - Advent Air ticked up 1/2 to 13-1/4 pence after the company revealed a 245 pct leap in first-half pretax profits on the back of gr[16 Mar '07]
SR Pharma says FDA approves investigational application for second siRNA product
LONDON (AFX) - SR Pharma PLC said the US Food and Drug Administration has approved an Investigational New Drug application for a second small in[16 Mar '07]
SR Pharma to get 1.5 mln usd milestone payment as blindness drug trial starts
LONDON (AFX) - Biopharmaceutical company SR Pharma PLC said it will get a 1.5 mln usd milestone payment to mark the start of a clinical trial on[5 Feb '07]
SR Pharma to conduct full toxicological evaluation of RNAi candidate Atu027
LONDON (AFX) - Biopharmaceutical company SR Pharma PLC said it will proceed with a full, 28-day toxicological evaluation of its RNAi product can[30 Jan '07]
RPT SR Pharma granted core RNAi patent by European Patent Office
(repeating to remove text from bottom of story) LONDON (AFX) - SR Pharma plc said the European Patent Office has granted the company its cor[3 Jan '07]
